EICHORPublic-registry site landscape for NCT06365853, “A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression”, a Recurrent Ovarian Cancer study sponsored by AbbVie. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT06365853 (registry record) |
| Study title | A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression |
| Official title | A Randomized Phase 2 Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Patients With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression |
| Sponsor | AbbVie |
| Condition(s) | Recurrent Ovarian Cancer; Folate Receptor-Alpha Positive |
| Phase | PHASE2 |
| Listed sites | 40 |
| Site countries | United States, Australia, Belgium, Canada, France, Ireland, Spain |
Patient-friendly overview of this study: eichor.com/study/NCT06365853.
Eichor generates a preliminary site-risk snapshot for NCT06365853 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Recurrent Ovarian Cancer trials
More from AbbVie
← Eichor home · All tracked trials · Recurrent Ovarian Cancer studies · Weekly briefs
